Five diabetes drugs among top selling drugs in India
Five anti-diabetes drugs are amongst the top-10 selling medicines in India.
This is a major shift from the earlier trend when the organized retail pharma market was dominated by anti-infectives and antibiotics, according to a web posting by Brand India Pharma, a unit of India’s Pharmaceutical Export Promotion Council (Pharmexcil). Control of non-communicable disease has been one of the greatest challenges for the country.
The anti-diabetic therapy segment is estimated to be worth 85 billion rupees ($1.29 billion) and is growing at a strong rate of 12%, according to data from AIOCD Awacs. Human Mixtard (insulin from Abbott), Glycomet GP (metformin), Lantus (insulin glargine from Sanofi), Galvus Met (vildagliptin from Novartis) and Janumet (sitagliptin/metformin from Merck & Co) are the five top selling anti-diabetics drugs. The number of diabetes drugs in the top 10 selling drugs has increased from one in June 2013 to five in June 2016.
Factors affecting the surge
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze